Aptamer Group Plc · LSE:APTA
Aptamer — H1 FY2025 Earnings Presentation
15 slides from Aptamer's earnings presentation, March 2025
Slide 1: Aptamer Group plc: Results for six months to 31 December 2024
Aptamer Group plc Results for six months to 31 December 2024 Investor presentation
Slide 2: Disclaimer
DISCLAIMER This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking statements are not based on historical facts but rather on expectations and
Slide 3: Presentation team
Presentation team Dr Arron Tolley Andrew Rapson Chief Executive Chief Financial Officer Officer ‒ Co-founded Aptamer Group in 2008 ‒ Over 20 years of finance experience, ‒ Globally-recognised technical and including AIM listed companies commercial leader in aptamers ‒ Chartered Accountant ‒ Delivere
Slide 4: Business overview
Business overview Recognised as a key global player in aptamer development 1 in the $210bn affinity ligand market 2 Two proprietary discovery platforms for custom binders Relationships with all the Top 10 global pharma companies 3 - Incorporated in 2008 - Headquartered in York, UK - AIM IPO in Dec 2
Slide 5: Two proprietary discovery platforms
Two proprietary discovery platforms Technical advantages Optimer® binders are optimised DNA or RNA aptamers. • Broader target applicability Automated, high-throughput discovery and development platform. • Tuneable selectivity and tailored to end application • Speed of discovery • Scalable cost-effec
Slide 6: Financial review
Financial review
Slide 7: Income statement and cashflow statement
Income statement and cashflow statement Period ended Period ended Revenue of £0.7m (H1 2024: £0.3m) 31 Dec ‘24 31 Dec ‘23 Income Statement £’000 £’000 Admin expenses £1.5m (H1 2024: £1.7m) Revenue 653 298 • Fixed cost base reduced to c.£3.0m Cost of Sales (286) (324) • Leaner Senior Leadership Team
Slide 8: Balance sheet
Balance sheet Year ended Year ended 31 Dec 24 30 Jun 24 £’000 £’000 Net assets of £2.6m (June 2024: £0.9m) Other intangible assets 183 165 • Equity raise in the period of £2.6m with the issuance of 1.45bn shares at 0.2p Property, plant & equipment 358 424 Right-of-use assets 154 187 Other receivable
Slide 9: Operational review
Operational review @ aptamer
Slide 10: Board and strategic focus update
Board and strategic focus update Dr Adam Dr Arron Tolley Andrew Rapson Dr David Bunka Tim Sykes Hargreaves Chief Executive Chief Financial Chief Scientific Non-Exec Non-Exec Officer Officer Officer director Chair In August 2024, the Board was restructured with Dr Adam Hargreaves appointed as Non-Exe
Slide 11: Fee-for-service developments
Fee-for-service developments New contracts signed • Four agreements with top 20 pharmaceutical and leading biotechnology companies for Optimer development as critical reagents to support therapeutic development programmes. • Extension contract signed with top 20 pharmaceutical partner in December 20
Slide 12: High value Optimer assets
High value Optimer® assets Optimer® developed as potential active Developing Optimer®-based diagnostic Optimer® delivery vehicle for precision ingredient in deodorant. for Alzheimer’s disease. medicines in fibrotic liver. Alzheimer’s disease test Optimer® for deodorant Partnered with largest global
Slide 13: Increased number of licensing opportunities
Increased number of licensing opportunities Asset Partner Optimer® for deodorant Unilever Optimer® critical reagent Top 5 pharma company Optimer® for Alzheimer’s Neuro-Bio disease diagnostic Fibrotic liver delivery vehicle AstraZeneca 4 10 opportunities H1 FY25 Global life science enzyme provider op
Slide 14: Investment case
Investment case Optimer® for deodorant Alzheimer’s diagnostic Drug delivery vehicles with with Unilever with NeuroBio AstraZeneca FFS arm targeting the $210bn 02 Developing high-value assets with strategic partners affinity ligand market1 to to target future licensing revenue meet demand for antibod
Slide 15: Questions?
we °° °° °°» Questions? @ aptamer